The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

ZUMA-12: Is CAR T-cell therapy effective in high-risk DLBCL as first-line therapy?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Sattva Neelapu, MD Anderson Cancer Center, Houston, US, about the ZUMA-12 study. We asked, Is chimeric antigen receptor T-cell therapy effective in high-risk diffuse large B-cell lymphoma (DLBCL) as first-line therapy?

ZUMA-12: Is CAR T-cell therapy effective in high-risk DLBCL as first-line therapy?

Neelapu reports the promising results from the interim analysis of the phase II ZUMA-12 study, evaluating axicabtagene ciloleucel as first-line therapy in patients with high-risk DLBCL.


Share: